Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04439071 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
A Phase 2 study, sponsored by PTC Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
NCT04439071 is a Phase 2 study that was terminated before completion, run by PTC Therapeutics. The registered enrollment target is 189 participants.
The verdict
NCT04439071, a Phase 2 study, was terminated before completion, sponsored by PTC Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
Interventions
- DRUG Placebo
- OTHER SOC
- DRUG PTC299
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2022-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04439071
The ClinicalTrials.gov registry entry for NCT04439071 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04439071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04439071 about?
NCT04439071 is a clinical study titled "A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)". This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
What is the current status of trial NCT04439071?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2020-07-09. Estimated completion is 2022-07-20.
What interventions are being tested in trial NCT04439071?
The interventions under investigation include: Placebo (DRUG), SOC (OTHER), PTC299 (DRUG).
Who is sponsoring clinical trial NCT04439071?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.